Compare JUBILANT LIFE SCIENCES with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES ABBOTT INDIA JUBILANT LIFE SCIENCES/
ABBOTT INDIA
 
P/E (TTM) x 14.8 43.2 34.4% View Chart
P/BV x 1.7 12.4 14.0% View Chart
Dividend Yield % 0.9 0.6 154.1%  

Financials

 JUBILANT LIFE SCIENCES   ABBOTT INDIA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
ABBOTT INDIA
Mar-18
JUBILANT LIFE SCIENCES/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs8986,110 14.7%   
Low Rs6183,996 15.5%   
Sales per share (Unadj.) Rs572.01,552.2 36.9%  
Earnings per share (Unadj.) Rs36.2188.8 19.2%  
Cash flow per share (Unadj.) Rs59.5196.4 30.3%  
Dividends per share (Unadj.) Rs4.5055.00 8.2%  
Dividend yield (eoy) %0.61.1 54.6%  
Book value per share (Unadj.) Rs301.9796.6 37.9%  
Shares outstanding (eoy) m159.2821.25 749.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.3 40.7%   
Avg P/E ratio x20.926.8 78.2%  
P/CF ratio (eoy) x12.725.7 49.5%  
Price / Book Value ratio x2.56.3 39.6%  
Dividend payout %12.429.1 42.6%   
Avg Mkt Cap Rs m120,694107,376 112.4%   
No. of employees `0002.43.3 71.9%   
Total wages/salary Rs m19,2603,937 489.2%   
Avg. sales/employee Rs Th38,120.69,929.3 383.9%   
Avg. wages/employee Rs Th8,058.41,185.1 680.0%   
Avg. net profit/employee Rs Th2,414.31,207.7 199.9%   
INCOME DATA
Net Sales Rs m91,10832,985 276.2%  
Other income Rs m3571,170 30.5%   
Total revenues Rs m91,46634,155 267.8%   
Gross profit Rs m17,3905,245 331.6%  
Depreciation Rs m3,709162 2,290.9%   
Interest Rs m2,19838 5,754.2%   
Profit before tax Rs m11,8406,215 190.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,2682,203 148.4%   
Profit after tax Rs m5,7704,012 143.8%  
Gross profit margin %19.115.9 120.0%  
Effective tax rate %27.635.4 77.9%   
Net profit margin %6.312.2 52.1%  
BALANCE SHEET DATA
Current assets Rs m45,84822,655 202.4%   
Current liabilities Rs m20,8976,681 312.8%   
Net working cap to sales %27.448.4 56.5%  
Current ratio x2.23.4 64.7%  
Inventory Days Days5765 87.7%  
Debtors Days Days5129 174.7%  
Net fixed assets Rs m65,498835 7,839.7%   
Share capital Rs m159213 75.0%   
"Free" reserves Rs m47,93016,715 286.7%   
Net worth Rs m48,08916,928 284.1%   
Long term debt Rs m42,4290-   
Total assets Rs m114,68524,162 474.7%  
Interest coverage x6.4163.7 3.9%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.81.4 58.2%   
Return on assets %6.916.8 41.4%  
Return on equity %12.023.7 50.6%  
Return on capital %12.436.9 33.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,422369 3,370.6%   
Fx outflow Rs m17,2273,807 452.6%   
Net fx Rs m-4,805-3,438 139.8%   
CASH FLOW
From Operations Rs m11,2151,527 734.5%  
From Investments Rs m-10,118-2,148 471.0%  
From Financial Activity Rs m6,574-1,024 -641.8%  
Net Cashflow Rs m7,612-1,646 -462.6%  

Share Holding

Indian Promoters % 45.6 0.0 -  
Foreign collaborators % 3.5 75.0 4.7%  
Indian inst/Mut Fund % 8.7 7.9 110.1%  
FIIs % 21.2 0.1 21,200.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 17.1 123.4%  
Shareholders   23,815 18,270 130.4%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 19, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS